Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 52

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 52
---
 not approved by security holders |     |                                      |         — |     |                |    — |     |                  |         — |    |
| Total                                                      |     |                                      | 3,700,335 |     | $              | 5.87 |     |                  | 1,035,918 |    |

| (1) | The weighted average exercise price is calculated based solely on outstanding stock options. |

| (2) | Includes our 2020 Plan. |

| (3) | Consists of 1,035,918 shares of our common stock available for issuance under the 2020 Plan as of December 31, 2024. As of February 6, 2025, we ceased making grants under the 2020 Plan and, instead, make grants under the 2025 Plan. |

35

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS Certain Relationships and Transactions Other than the compensation agreements and other arrangements described under “Executive Compensation” and “Director Compensation” in this proxy statement and the transactions described below, since January 1, 2023, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of our total assets amounts at December 31, 2023 and 2024) and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest. Series C Preferred Stock Financing On March 4, 2024, in an initial closing and a subsequent closing, we issued and sold 17,717,162 and 911,808 shares of our Series C convertible preferred stock, par value $0.001 per share (“Series C preferred stock”), respectively, representing an aggregate of 18,628,970 shares of Series C preferred stock, at a purchase price of $9.762 per share, for an aggregate purchase price of approximately $181.9 million. Each outstanding share of Series C preferred stock converted into shares of common stock at a ratio of 1-for-1.4611immediately prior to the completion of our initial public offering. The following table summarizes the shares of our Series C preferred stock